Since 2011, more than 76,000 provisions of assistive technology and devices have been coordinated and documented via the APST Internet platform. Approximately 9,000 patients as well as
Nusinersen (Spinraza®) is an approved drug for the treatment of 5q-associated Spinal Muscular Atrophy (SMA). Infants and children treated with Nusinersen may experience cessation of disease
